Onesource Specialty Pharma Q2 Results: Stock jumps 8% on strong operating performance, revenue growth

What happened

OneSource Specialty Pharma reported net profit of ₹57.4 crore, up from ₹10.4 crore, and revenue of ₹516.2 crore, up 37.4% from ₹376 crore a year earlier. EBITDA rose 53% to ₹163.2 crore.

Confirmed

Global impact / market context

A wider profit per sale means the company keeps more from each rupee of revenue. EBITDA margin, which shows operating profit as a share of revenue, rose to 31.6%, so earnings growth outpaced revenue growth and supports investor confidence.

Analyst inference

The stock is still 23% below its 52-week high of ₹1,925, so the 6.4% gain is a partial rebound. It reflects investors rewarding profit and revenue growth rather than price momentum alone.

Analyst inference

What to watch

1. Watch whether revenue growth of 37.4% and an EBITDA margin of 31.6% hold in coming quarters. Confirmed
2. The company should disclose more details, since the article says the story will be updated, so investors can judge whether growth is repeatable. Proposed
3. Watch the gap to the 52-week high of ₹1,925; closing it depends on continued profit growth and stable costs, not just one strong quarter. Analyst inference

Evidence

• Original source link unavailable